Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection

Journal of Pediatric Gastroenterology and Nutrition

Volumn 51, Issue 2, 2010, Pages 191-197

  Delgado Borrego, Aymin ^a   Healey, David ^b   Negre, Betania ^a   Christofi, Marielle ^b   Sabharwal, Sabina ^c   Ludwig, David A ^a   Chung, Raymond T ^c   Jonas, Maureen M ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

fibrosis; interferon; obesity; pediatric; steatosis

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEPATITIS C; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SCHOOL CHILD; SCORING SYSTEM; STEATOSIS; TREATMENT RESPONSE;

ADOLESCENT; ANTIVIRAL AGENTS; BODY MASS INDEX; CHILD; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; FATTY LIVER; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; OBESITY; RETROSPECTIVE STUDIES;

HEPATITIS C VIRUS;

EID: 77955228622     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181d32756     Document Type: Article

References (36)

1. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-1555
2. Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986-1998. JAMA 2001;286:2845-2848
3. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes 2006;1:11-25.
4. Sabin MA, Shield JP. Childhood obesity. Front Horm Res 2008;36:85-96.
5. Lob-Corzilius T. Overweight and obesity in childhood-a special challenge for public health. Int J Hyg Environ Health 2007;210:585-589
6. Lee WW. An overview of pediatric obesity. Pediatr Diabetes 2007;8 (Suppl 9):76-87.
7. Lobstein T, Millstone E. Context for the PorGrow study: Europe's obesity crisis. Obes Rev 2007;8(Suppl 2):7-16.
8. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006;43:1177-1186
9. Younossi ZM, McCullough AJ, Ong JP, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004;38:705-709
10. Hu KQ, Kyulo NL, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol 2004; 40:147-154
11. Ortiz V, Berenguer M, Rayon JM, et al. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002;97: 2408-2414
12. Hsieh MH, Lee LP, Hsieh MY, et al. Hepatic steatosis and fibrosis in chronic hepatitis C in Taiwan. Jpn J Infect Dis 2007;60:377-381
13. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004;40:484-490
14. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562
15. Gonzalez-Peralta RP. Treatment of chronic hepatitis C in children. Pediatr Transplant 2004;8:639-643
16. Gonzalez-Peralta RP, Kelly DA, Haber B, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005; 42:1010-1018
17. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002;36:S1-2.
18. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003;7:261-287
19. Harrison SA, Brunt EM, Qazi RA, et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005;3:604-609
20. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128:636-641
21. Lo Iacono O, Venezia G, Petta S, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007; 25:1181-1191
22. Bressler BL, Guindi M, Tomlinson G, et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-644
23. Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006;55:529-535
24. Tarantino G, Conca P, Sorrentino P, et al. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol 2006;21:1266-1268
25. Gheorghe L, Iacob S, Sporea I, et al. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. J Gastrointestin Liver Dis 2007; 16:23-29
26. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
27. Blonsky JJ, Harrison SA. Review article: nonalcoholic fatty liver disease and hepatitis C virus-partners in crime. Aliment Pharmacol Ther 2008;27:855-865
28. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008;48:28-34.
29. Soresi M, Tripi S, Franco V, et al. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int 2006;26:1119-1125
30. GiannattasioA, Spagnuolo MI, Sepe A, et al. Is HCVinfection associated with liver steatosis also in children? J Hepatol 2006;45:350-354 (Pubitemid 44142107)
31. Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008;47:836-843
32. Westin J, Nordlinder H, Lagging M, et al. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002;37:837-842
33. Hesketh K. Stability of body mass index in Australian children: a prospective cohort study across the middle childhood years. Public Health Nutr 2003;7:303-309
34. Katzmarzyk PT. Seven-year stability of indicators of obesity and adipose tissue distribution in the Canadian population. Am J Clin Nutr 1999;69:1123-1129
35. St George A, Bauman A, Johnston A, et al. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol 2009;24:399-407.
36. Vitola BE, Deivanayagam S, Stein RI, et al.Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents. Obesity (Silver Spring) 2009;17:1744-1748